XML 18 R6.htm IDEA: XBRL DOCUMENT v3.25.1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT) (Unaudited) - USD ($)
Total
Common Stock
Treasury Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Non-controlling Interests
Balance, beginning of period (in shares) at Dec. 31, 2023   124,659          
Balance, beginning of period at Dec. 31, 2023 $ 2,580,605 $ 5,927   $ 155,615,962 $ 93,676 $ (148,240,859) $ (4,894,101)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Exercise of stock options and vesting of restricted stock (in shares)   17,414          
Exercise of stock options and vesting of restricted stock 0 $ 18   (18)      
Stock-based compensation 846,514     846,514      
Proceeds from common stock offering, net of offering costs (in shares)   303,500          
Proceeds from common stock offering, net of offering costs 5,029,422 $ 304   5,029,118      
Issuance of Pre-funded Warrants (in shares)   161,492          
Issuance of Pre-funded Warrants 108 $ 108          
Currency translation adjustment (13,651)       (13,651)    
Preferred dividends - non-controlling interest (75,004)           (75,004)
Accretion on redeemable non-controlling interests preferred shares (161,466)           (161,466)
Net loss (6,728,737)         (6,714,438) (14,299)
Balance, end of period (in shares) at Mar. 31, 2024   607,064          
Balance, end of period at Mar. 31, 2024 1,477,791 $ 6,357   161,491,576 80,025 (154,955,297) (5,144,870)
Balance, beginning of period (in shares) at Dec. 31, 2023   124,659          
Balance, beginning of period at Dec. 31, 2023 $ 2,580,605 $ 5,927   155,615,962 93,676 (148,240,859) (4,894,101)
Balance, end of period (in shares) at Dec. 31, 2024 904,949 903,269          
Balance, end of period at Dec. 31, 2024 $ (1,289,647) $ 6,408 $ 0 164,285,336 46,494 (165,599,076) (28,809)
Balance, end of period (in shares) at Dec. 31, 2024 1,680   1,680        
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock-based compensation $ 554,659     554,659      
Proceeds from Direct Offering, net of offering costs (in shares)   213,428          
Proceeds from Direct Offering, net of offering costs 564,868 $ 21   564,847      
Exercise of Warrants (in shares)   431,652          
Exercise of Warrants 854,096 $ 43   854,053      
Conversion of Convertible Notes (in Shares)   1,568,019          
Conversion of Convertible Notes, net of offering costs 2,952,583 $ 157   2,952,426      
Currency translation adjustment 236       236    
Net loss $ (6,878,601)         (6,873,003) (5,598)
Balance, end of period (in shares) at Mar. 31, 2025 3,116,368 3,116,368          
Balance, end of period at Mar. 31, 2025 $ (3,241,806) $ 6,629 $ 0 $ 169,211,321 $ 46,730 $ (172,472,079) $ (34,407)
Balance, end of period (in shares) at Mar. 31, 2025 1,680   1,680